Today, Scantox, along with its majority owner Impilo, has successfully concluded the acquisition of QPS Neuropharmacology, a leading contract research organization (CRO) specializing in drug discovery for neurodegenerative diseases, rare conditions, and mental disorders. Following the integration into the Scantox Group as Scantox Neuro, the company's renowned high-quality services deeply rooted in scientific rigor will be augmented, boasting an esteemed track record of serving a diverse and loyal clientele globally. This strategic acquisition substantially enriches Scantox's value chain coverage, particularly bolstering its unique and leading-edge central nervous system (CNS) research capabilities.

Founded in 1999, the former QPS Neuropharmacology has cultivated extensive expertise in lead optimization services and efficacy studies over its long history. Situated in a state-of-the-art facility spanning 2,700 square meters in Grambach, Austria, and boasting a workforce exceeding 80 professionals, the company is equipped with validated transgenic and non-transgenic in vitro and in vivo models, enabling it to target multiple entities within the burgeoning realm of CNS. Consequently, it stands as an unparalleled collaborator for biotechnology and pharmaceutical enterprises in advancing their drug development endeavors.

Jeanet Løgsted, CEO of Scantox Group, remarked, "Since the announcement of our intent to acquire QPS Neuropharmacology in November, we've diligently prepared for the expansion of our operations. This represents a transformative addition to our Discovery division, significantly enhancing our lead optimization platform and broadening the scope of our services in CNS and rare diseases. Scantox's trajectory of rapid expansion persists, ensuring our global clientele receive an ever-elevated standard of service and scientific prowess."

Manuela Prokesch, Director of Scantox Neuro GmbH, added, "Joining the Scantox Group unlocks unparalleled opportunities for us to offer an even more comprehensive portfolio of services to our clients. As an entity, we eagerly anticipate assimilating into a highly reputable European CRO, where we can capitalize on synergies and sustain our growth trajectory together."

Under the newly formed Neuro entity, Scantox Group will boast over 300 professionals across six locations, offering a spectrum of services encompassing lead optimization, regulatory toxicology, and CMC/analytical services.

Nicholas Hooge, Partner at Impilo, concluded, "The completion of this acquisition enables Scantox to substantially broaden its service spectrum and market presence. We extend a warm welcome to the Austrian team into the Scantox fold and envision significant growth prospects for the amalgamated entity in the future."

 

Source: prnewswire.com

Report Abuse